NEXGEL INC
NXGLNASDAQTrading Snapshot
- Day Range
- $3.80 β $4.30
- 52-Week Range
- $3.00 β $53.60
- Volume (shares)
- 52,510
- Avg Volume (shares)
- β
- Shares Outstanding
- 21,189
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $4M
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-274.49
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.6%
NEXGEL INC
NXGLAbout NEXGEL INC
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

NEXGEL Regains Compliance with Nasdaq Listing Requirement
LANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (βNEXGELβ or the βCompanyβ) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to p

NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript

NEXGEL Announces Dial-In Details for Investor Update Call
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians t

NEXGEL Announces Date for Investor Update Call
LANGHORNE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians t

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
LANGHORNE, Pa. , Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational

NEXGEL Reports Second Quarter 2026 Financial Results
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (βNEXGELβ or the βCompanyβ) (NASDAQ: βNXGLβ), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-wate